Correlation between abnormal GSK3 beta, beta Amyloid, total Tau, p-Tau 181 levels and neuropsychological assessment total scores in CKD patients with cognitive dysfunction: Impact of rHuEPO therapy

摘要

Background: Cognitive dysfunction potentially affecting up to 60% of CKD patients. GSK-3 beta plays a key role in the pathogenesis of AD and Cognitive dysfunction, contributing to A beta production and A beta-mediated neuronal death by phosphorylating tau inducing hyperphosphorylation in paired helical filaments. However, studies have shown that plasma p-Tau181 is more specific for AD and cognitive dysfunction. Anemia is a vital risk factor for cognitive dysfunction in CKD patients. EPO is usually to treat anemia in CKD and also improved in cognitive function. The aim of the study is to correlate between the impacts of rHuEPO therapy on platelet GSK3 beta expression, plasma A beta. total Tau, p-Tau 181 levels and neuropsychological assessments total scores in CKD patients with Cognitive dysfunction.